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Available online xxxxMagnetic resonance imaging (MRI) is an invaluable tool for the diagnosis and monitoring of patients with mul-
tiple sclerosis (MS) aswell as for the study of the disease pathophysiology. Because of its strong clinical, radiolog-
ical and histopathological similarities with the human disease, experimental autoimmune encephalomyelitis
(EAE) in the commonmarmoset has been studiedmore intensively over the past several years. Here, we review
the current knowledge on MRI in the marmoset EAE, and we outline the physiopathological significance and
translational values of these studies with respect to MS. Accumulating evidences suggest that the application
of conventional, as well as non-conventional, MRI techniques in the marmoset EAE is a promising approach to
elucidate the pathological processes underlying the development of inflammatory demyelinated lesions in the
central nervous system, potentially improving the identification and development of new therapeutics.








Multiple sclerosis (MS) is an immune-mediated disease of the cen-
tral nervous system (CNS) pathologically characterized by the presence
of focal demyelinated lesions in brain and spinal cord (Lassmann et al.,
2007; Hohlfeld et al., 1995). Clinically, themost common formofMS be-
gins with a relapsing remitting (RR) phase, characterized by neurologi-
cal symptoms that partially or fully recover within days or weeks.
Patients can remain in this phase for the whole life (~20% cases, benign
MS (Hawkins and McDonnell, 1999)) or switch to a progressive phase,
named secondary progressive (SP) MS, characterized by accumulation
of clinical disability over time. Although overt inflammation plays a
major role in the first RR phase of the disease, the progressive phase
seems mainly characterized by neurodegeneration with mostly com-
partmentalized inflammation (Absinta et al., 2015; Fischer et al., 2013).
At present, valid therapeutic options are available only for the RR
phase of MS and no curative treatment exists. Indeed, the available
treatments are more effective early in the course of the disease, when
tissue damage and neurodegenerative processes are still minimal or ab-
sent. In order to further improve knowledge on the early treatable phase
of the disease, recent research has been focusing on the sequence of
events underlying the development of inflammatory lesions (Frohman
et al., 2006). Although the “primummovens” determining these lesions
to develop in the CNS is still largely unknown, an autoimmune reaction
directed against CNS components, developing in a genetically and envi-
ronmentally suitable background, is thought to be the base of thisnetic resonance imaging of ex
0.1016/j.jneuroim.2016.09.01disease (t Hart andMassacesi, 2009). In this context, the close immuno-
pathological similarities between the lesions observed in MS and in ex-
perimentally induced autoimmune encephalomyelitis (EAE) allowed to
consider EAE a valid model of the effector pathogenic mechanisms of
MS (t Hart and Massacesi, 2009).
1.1. Advantages and limits of the EAE model
The EAE model indeed is a well characterizedmodel of CNS autoim-
munity. The disease is induced by immunization of recipient animals
with CNS antigens or myelin components together with an adjuvant,
causing an autoimmune reaction against the CNS. EAE can be induced
in a large variety of species (Baxter, 2007), but only a few forms of
EAE are both clinically and pathologically close to MS. Indeed, the clini-
cal and pathological features of this disease vary among the different
species in which it was induced (mice, rats, rabbits, guinea pigs and
monkeys) and among differentmodels (based on the type ofmyelin an-
tigen used to induce the disease), ranging from an acute monophasic
disease to a relapsing-remitting one closer to human MS (t Hart and
Massacesi, 2009).
Both in MS and EAE, the histopathology of the acute lesions, is char-
acterized by inflammatory infiltrates, mostly lymphocytes and macro-
phages, cuffed around post capillary venules (Baxter, 2007). Despite a
substantial histopathological similarity, the main difference between
the two diseases is the artificial induction of autoimmunity in EAE
whereas the causes of MS are less clear. Thus the first phase (afferentperimental autoimmune encephalomyelitis in the commonmarmoset,
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tem begins to mount an autoimmune response against the CNS – defin-
itively differs between the two diseases. Nonetheless, the close
histopathological similarity between MS and EAE suggests that the sec-
ond phase (the effector arm) of the immune responsemay be very sim-
ilar (t Hart and Massacesi, 2009). In this contest EAE is widely
considered a valid model to study the effector arm of MS pathogenesis.
As a proof of relevance, three therapeutics commonly used to treat MS
patients have been developed on the ground of EAE models: glatiramer
acetate, mitoxantrone and natalizumab (Yednock et al., 1992). Howev-
er, a large number of other potential therapies effective in mice EAE
failed to have clinical efficacy in human MS (Sriram and Steiner, 2005;
Steinman and Zamvil, 2006). This is likely to be due to the large evolu-
tionary distance between rodents and humans. In addition, inbred lab-
oratory mice lack a pathogen-educated immune system, an important
discrepancy with the human disease where infections are thought to
play a crucial role in pathogenesis (Lathrop et al., 2011). Lesions in the
mice EAE model are mostly confined to the brain stem and spinal cord
and the pathology often does not includes demyelination (Hauser,
2015). Moreover, the small size of the mice brain makes them unsuit-
able for in vivoMRI studies (Jordan et al., 1999; Hart et al., 1998). There-
fore the development of an EAE model in larger animals, with a closer
evolutionary relationship to human, allowed to bridge the gap between
mice EAE and human MS (Kap et al., 2010).
1.2. EAE in the common marmoset
Nonhuman primates are genetically, immunologically, and microbi-
ologically closer to humans, and for this reason EAE has been developed
in old and new world monkeys. EAE in macaques (old world monkeys)
is characterized by an hyperacute destructive CNS disease usually caus-
ing the death of the animal within a few days after onset (t Hart and
Massacesi, 2009; Kap et al., 2010; t Hart et al., 2000), thus making this
model closer to acute disseminated encephalo-myelitis than to MS. On
the other hand, EAE in the common marmoset (new world monkey)
creates a CNS disease very similar to MS. The common marmoset
(Callitrix jacchus) is a small monkey with an adult weight of 300–
400 g (t Hart et al., 2000). Female marmosets commonly give birth to
two non-identical twins. These twins are bonemarrow chimeras, a fea-
ture that allows transfer of immune cells between twins, evenwhen not
identical, without inducing rejection (Genain and Hauser, 1996). Two
main marmoset EAE models have been developed so far. The first
model, originally described by Massacesi et al., is induced with white
matter (WM) homogenate (WMH) (Massacesi et al., 1995) giving
perivenular brain and spinal cord WM lesions (t Hart and Massacesi,
2009; Gaitan et al., 2013) pathologically resembling the lesions ob-
served in MS autopsies. The second model, induced with recombinant
human myelin oligodendrocite glycoprotein (rhMOG) gives generally
fewer but larger demyelinated lesions. Although the rhMOG model re-
capitulates many of the pathological and immunological aspects of
human MS (tHart et al., 2015), in our experience the disease in this
model appearsmore aggressive, sometimes hemorrhagic, and therefore
less close to MS than the former one (Gaitan et al., 2013).
An important difference between the marmosets and the pathogen-
free laboratory rodents is the natural exposure to environmental infec-
tions. As it happens in humans, the development of themarmoset's im-
mune system is influenced by environmental pathogens and chronic
latent infections (tHart et al., 2015; Leibovitch et al., 2013). It has been
hypothesized that through a mechanism of brain-pathogen antigen
cross-recognition and/or direct cellular infection, these environmental
pathogens play an important role in the development of autoimmunity
both in MS and in EAE (Berer et al., 2011). Being genetically, immuno-
logically and environmentally closer to humans compared to laboratory
mice, EAE in the marmosets can well recapitulate the most important
MS susceptibility factors: genes and the environment. Additionally,
the relatively small size of these primates and the higher white-to-Please cite this article as:Maggi, P., et al.,Magnetic resonance imaging of ex
J. Neuroimmunol. (2016), http://dx.doi.org/10.1016/j.jneuroim.2016.09.01graymatter ratio compared to rodent brains make them highly suitable
to study in vivo the development of white matter brain lesions bymag-
netic resonance imaging (MRI).
1.3. Magnetic resonance imaging in marmoset EAE
MR imaging is an essential tool for the diagnosis and monitoring of
patients with MS, but it can also provide a window into the disease
pathogenesis. However, the underlying biology of the MRI findings is
often difficult to establish in human studies. This issue can be overcome
with animalmodels which enable a direct comparison ofMR images ac-
quired in vivo with histopathology performed post mortem. Another
advantage of animal models is the possibility to obtain pre-morbid MR
images and to follow the development of brain lesions from the time
of their first appearance until the termination of the experiment
(Gaitan et al., 2013; Maggi et al., 2014a). Similarly to human studies,
conventional and non-conventional MRI techniques can be applied to
these animals, thus allowing to better understand the biological corre-
lates of the MRI findings, as well as validating novel more specific MRI
markers of the different damages (such as demyelination, axonal pa-
thology, iron deposition) occurring in brain lesions.
1.4. Conventional MRI techniques
In MS, conventional MRI techniques such as T2-weighted (T2w),
proton-density weighted (PDw) and T1-weighted (T1w) sequences
are commonly used to follow the development of new brain lesions
over time as well as to evaluate the evolution of older lesions (Polman
et al., 2011). The same techniques can be applied to the marmoset
EAE at various magnetic field strengths (1.5 T, 3 T and 7 T) (Jordan
et al., 1999; Gaitan et al., 2013; Maggi et al., 2014a; Blezer et al., 2007;
Helms et al., 2013). Similarly to MS, newWM lesions in the marmoset
EAE appear hyperintense on T2w and PDw and hypointense on T1w se-
quences. The hyperintense signal in both T2w and PDw is nonspecific,
and can be correlated with both inflammation and tissue damage in-
cluding demyelination. Within a few weeks after lesion appearance,
the hyperintense focal area tends to reduce in size, possibly because of
reabsorption of perilesional edema (t Hart and Massacesi, 2009). In
the marmoset EAE, this shrinkage of the T2w hyperintense area also
correlates with partial remyelination (Maggi et al., 2014a). Longitudinal
MRI of the marmoset EAE demonstrates that new lesions develop over
time and can form in any of the functional systems of the CNS, thus re-
producing the classic pattern of lesion development in MS with both
dissemination in time and space (t Hart and Massacesi, 2009; Jordan
et al., 1999).
The different locations of EAE lesions in the brain (periventricular,
juxtacortical, infratentorial) reproduce MS lesions (t Hart and
Massacesi, 2009) [Fig. 1]. Moreover, EAE lesions tend to develop around
parenchymal veins, similarly to MS (Adams and Kubik, 1952). This was
recently demonstrated using susceptibility-based imaging, also called
T2*-weighted (T2*w) imaging, which is particularly sensitive to the
magnetic susceptibility of venous blood (Sati et al., 2014; Maggi et al.,
2014b). On T2*w images, EAE lesions in the white matter appear as
focal hyperintensities with a hypointense line (central vein) running
through them (Sati et al., 2014) [Fig. 2]. Availability of T2*w images be-
fore EAE induction, as well as frequent T2*w imaging following induc-
tion, allowed to demonstrate that EAE lesions develop around pre-
existing parenchymal veins (Gaitan et al., 2013).
Similarly to MS, gray matter (GM) pathology has also been reported
in themarmoset EAE (Pomeroy et al., 2005). Although deep GM lesions
can be observed byMRI inmarmoset EAE [Fig. 3], cortical GM lesions re-
maindifficult to detect in vivo, as thus far leukocortical lesions only have
been observed [Fig. 3]. The poor detection by MRI of intracortical and
subpial lesions is most likely due to the relative paucity of myelin in
the cortex (Ge, 2006), as well as the lower amount of edema in those
types of lesions (Lucchinetti et al., 2011).perimental autoimmune encephalomyelitis in the commonmarmoset,
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Fig. 1. Proton density-weighted images collected on a marmoset EAE showing the distribution of hyperintense lesions throughout the cerebral white matter.
Fig. 2. T2*-weighted images collected on a marmoset EAE showing the perivenular
distribution of white matter lesions (green arrows). (For interpretation of the references
to color in this figure legend, the reader is referred to the web version of this article.)
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J. Neuroimmunol. (2016), http://dx.doi.org/10.1016/j.jneuroim.2016.09.01Another common feature between MS and EAE lesions is related to
the integrity of the blood brain barrier (BBB) during the lesion develop-
ment. Similarly to MS lesions, the status of the BBB can be investigated
by MRI in marmoset EAE with the injection of gadolinium-based con-
trast agent (GBCA). When the BBB of newly formed lesions is leaking,
GBCA can penetrate the brain parenchyma and modifies the magnetic
properties of the brain tissue (GBCA shortens the longitudinal relaxa-
tion time (T1) of the tissue (Soon et al., 2007). This usually results in
an increase of signal intensity in the lesion area which is clearly visible
on T1w images acquired post- GBCA injection (Hart et al., 1998)
[Fig. 4]. Note that older (although still inflamed) lesions remain usually
hypo- or isointense on post-GBCA T1w images due to a closed BBB (our
data, unpublished).
1.5. Nonconventional MRI techniques
Over the past decade, various nonconventionalMRI techniques have
been developed to provide more specificity and/or more sensitivity to-
ward the pathological substrates of MS lesions. Some of these advanced
techniques (such as magnetization transfer imaging and T1
relaxometry) have also been applied to the marmoset EAE (Maggi
et al., 2014a; Blezer et al., 2007; Richards et al., 1995).
For example, magnetization transfer (MT) imaging is a semi-
quantitative technique that is sensitive to change in myelin content in
the CNS. A magnetization transfer ratio (MTR) image is generated
from the relative difference between two gradient-echo images ac-
quired with and without an off-resonance saturation pulse. Because
myelin is a lipid bilayer with a high macromolecule density, white mat-
ter will be more affected by the MT-saturation pulse, resulting in a
higher MTR value than for GM or CSF [Fig. 5]. In acute EAE lesions, a de-
crease in MTR has been associated with inflammation (Blezer et al.,
2007; t Hart et al., 2004) most likely due to the increased water content
from edema [Fig. 5]. Interestingly, a decrease in MTR was also reported
in normal-appearing white matter preceding MS lesion formation
(Filippi et al., 1998; Wuerfel et al., 2004). This MTR change may beperimental autoimmune encephalomyelitis in the commonmarmoset,
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Fig. 3. Proton density-weighted images collected on a marmoset EAE showing deep gray
matter lesions (green arrows) and a leukocortical lesion (red arrow). (For interpretation
of the references to color in this figure legend, the reader is referred to the web version
of this article.)
4 P. Maggi et al. / Journal of Neuroimmunology xxx (2016) xxx–xxxrelated to a subtle increase in BBB permeability occurring at the earliest
stages of lesion formation. This hypothesis was recently investigated in
the marmoset EAE using T1 relaxometry. Indeed, by acquiring T1 maps
before and after injection of GBCA, permeability of the BBB can be eval-
uated by the change in R1 (=1/T1) relaxation rate (Soon et al., 2007).
Analyzing 189 lesions from five different EAE animals, it was found
that the BBB becomes focally and increasingly permeable starting upFig. 4. T1-weighted images acquired before and after injection of gadolinium-based contrast a
injection image. The hypointense lesions (green arrows) on the pre-gad images become hype
on the difference image. (For interpretation of the references to color in this figure legend, the
Please cite this article as:Maggi, P., et al.,Magnetic resonance imaging of ex
J. Neuroimmunol. (2016), http://dx.doi.org/10.1016/j.jneuroim.2016.09.01to one month before the development of WM lesions (Maggi et al.,
2014a).
1.6. Comparison of MRI findings with histopathology
Pioneer studies investigating MRI lesions in the marmoset EAE
(Jordan et al., 1999)demonstrated that these are very similar to MS le-
sions visualized by MRI (t Hart and Massacesi, 2009). The characteriza-
tion of the pathology underlying different types of marmoset EAE brain
MRI lesions allowed for the first time to characterize also the heteroge-
neous repertoire of the different immune-pathological substrates of the
corresponding brain MRI lesions observed in MS. Noteworthy virtually
all the different MRI lesions described in MS could also be observed
and pathologically characterized in the marmoset EAE model (Hart
et al., 1998; Maggi et al., 2014a). Exactly as in MS early marmoset EAE
lesions are demyelinated, can occur both in WM and GM and show
Dawson's finger like site and shape, tending to develop around paren-
chymal veins, (Adams and Kubik, 1952; JM., 1868). A classic feature of
early MS lesions, commonly known as acute lesions, is the presence of
a cuff of inflammatory cells (mostly lymphocytes and dendritic cells)
around the central vein (Prineas andParratt, 2012). This is also observed
in marmoset EAE (Jordan et al., 1999), where acute lesions are associat-
ed with profound leakage of the blood brain barrier (BBB) allowing in-
flammatory cells and factors to enter the lesion parenchyma (Hart
et al., 1998; Maggi et al., 2014a; Katz et al., 1993). In the parenchyma
surrounding the central inflamed blood vessel, myelin is usually dam-
aged and picked up from large activated macrophages, exactly as in
MS (Hart et al., 1998; Maggi et al., 2014a; Prineas and Parratt, 2012).
Both in MS and marmoset EAE (Jordan et al., 1999) new inflammatory
lesions detected from Gd based MRI, are mainly associated to extensive
demyelination with relative sparing of the axons, whereas older lesions
are characterized by markedly reduced inflammatory activity associat-
ed to various degree of axonal damage (Hauser, 2015; Jordan et al.,
1999; Hart et al., 1998). Both inMS andmarmoset EAE inflammatory le-
sions not only T lymphocytes but also B cells are found (tHart et al.,
2015; Maggi et al., 2014a). In the animal model Genain et al. showed
that antibodies and presumably B cells are required for the develop-
ment of demyelination (Genain et al., 1996; Genain et al., 1995). This
is particularly relevant considering the increasing recognition that B
cells are gaining in MS pathogenesis and therapy development
(Absinta et al., 2015; Hauser, 2015). As in MS, also in marmoset EAE
(Pomeroy et al., 2005), the nature of both GMandWM lesions is inflam-
matory but WM lesions only are commonly associated with leakage of
the BBB (Lucchinetti et al., 2011). Noteworthy investigation of the path-
ological substrates of brain MRI finding is increasingly gaining impor-
tance in experimental neurosciences. For improving rapidity and
precision of this kind of investigation both in MS and marmoset EAE
brains, a novel simple method has recently been developed (Guygent. The difference image is obtained by subtracting the pre-injection image to the post-
rintense on the post-gad images. The enhancement of the acute lesions is best visualized
reader is referred to the web version of this article.)
perimental autoimmune encephalomyelitis in the commonmarmoset,
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Fig. 5.Magnetization transfer ratio images acquired before and after induction of EAE in a marmoset. White matter lesions generated by the disease (red arrows) display a decrease MTR
most likely due to edema and/or demyelination. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
5P. Maggi et al. / Journal of Neuroimmunology xxx (2016) xxx–xxxet al., 2015; Absinta et al., 2014). This method relies on custom-built 3D
printed brain holders to maintain the same brain orientation applied to
the in vivo MRI acquisition and the sectioning of histological slabs [Fig.
6]. This method reduces the burden of manually matching MRI and pa-
thology images at a relatively low monetary cost.
1.7. Lesion histopathology as a function of lesion age
For the histopathological characterization of the lesion evolution
process over time, serial in vivoMRI can be used to provide information
regarding the precise age of the lesions. Recent data on newly forming
lesions in MS (Gaitan et al., 2011; Absinta et al., 2013) have shown
how the dynamic pattern of contrast enhancement can give specific in-
formation about the age of a lesion, a parameter that in human MS au-
topsy studies it is difficult to directly establish. Indeed the time frame
between the first appearance of a lesion (potentially detectable with
in vivo brain imaging) and the death of the patient is usually deter-
mined only indirectly, by the quality of myelin degradation products
present within macrophages' and/or the expression of macrophage ac-
tivation markers (Bruck et al., 1995). Although this same approach has
been successfully applied tomarmoset histopathology by t'Hart and col-
leagues (t Hart and Massacesi, 2009), we recently showed a strategy to
in vivo precisely determine the age of a lesion in the marmoset EAE
model, by comparing the post mortem histopathology with the in vivo
imaging. As explained before in this paper, the acquisition of a serial
highly frequent in vivo data set and the availability of pre-morbidFig. 6.Whole-slicemach between in vivoMRI (PD-weighted), postmortemMRI (T2*-weightedM
highlight small demyelinated lesions detected on all three images. (For interpretation of the refe
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J. Neuroimmunol. (2016), http://dx.doi.org/10.1016/j.jneuroim.2016.09.01images, allows precise determination (in the order of days) of a lesion
age (Maggi et al., 2014a). Thus the entire process of lesion development
from its perivenular onset to its centrifugal expansion and, finally, its
shrinkage and repair, can be tracked over time. Consistently with the
in vivo T2* imaging results of Gaitan et al. (Gaitan et al., 2013), lesions
younger thanoneweekwere found to develop aroundveinswith a lym-
phocytic perivascular cuff surrounded by demyelination and by large
activated blood derived macrophages in the parenchima. These lesions
appear on T2-w images as focal hyperintensities in the brain WM and
are associated with elevated levels of BBB permeability as shown from
pre and post Gd T1 mapping. Interestingly, these early lesions resemble
the “phagocytic areas” described in MS pathology (Henderson et al.,
2009). Over theweeks, like inMS,we assist to an enlargement of the ini-
tial area of T2-w signal hyperintesity, as the process of inflammatory de-
myelination and its attendant activated blood derived macrophages
infiltration moves outward toward the lesion edges (Gaitan et al.,
2011; Henderson et al., 2009). Lesions older than five weeks appear as
small areas of residual T2-whyperintensity onMRI. These lesions shrink
over time and are associated to reduced levels of BBB permeability, sug-
gesting a reabsorption of the inflammatory oedema and repair. Indeed,
inflammatory cells and active demyelination are markedly reduced in
these lesions featuring pale myelin at the lesion borders, a pattern that
in MS has been related to remyelination (Lassmann, 2011). Pre and
post Gd T1 mapping MRI applied serially to the marmoset EAE brain
shows how the BBB becomes focally and increasingly permeable
starting up to one month before the appearance of T2w demyelinatedRI) andhistology (Luxol fast bluewith standardhematoxylin and eosin).Magnifiedboxes
rences to color in thisfigure legend, the reader is referred to theweb version of this article.)
perimental autoimmune encephalomyelitis in the commonmarmoset,
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corresponded on the histopathology, to small foci of perivascular lym-
phocytes andmicroglia activation without demyelination nor blood de-
rived macrophages infiltration (Maggi et al., 2014a).
In human MS studies, the pathological correlates of the prelesional
MRI changes detected by longitudinal nonconventionalMRI are difficult
to elucidate. Indeed, areas of future lesion development or prelesions
are rarely identified in MS biopsy samples due to the chronic nature of
the disease, with little new lesion formation later in the course of the
disease, and to the fact that acute MS lesions are only rarely fatal
(Barnett and Prineas, 2004). In the few histopathological studies avail-
able onMS early lesions, small areas of lymphocites perivascular cuffing
and parenchymal microglia activation have been hypothetized to be
areas of future lesion formation (Henderson et al., 2009). In these
early lesions BBB opening and fibrinogen leakage have been shown to
be crucial determinants for the activation of adaptive and innate im-
mune responses (Marik et al., 2007) (Davalos et al., 2012) and for the
development of autoimmunity in the CNS (Ryu et al., 2015). Similar
early lesions in the marmoset EAE feature indistinguishable rate of
BBB permeability increase over time compared to areas evolving in
demyelinated lesions. Thus, lymphocyte perivascular cuffing and mi-
croglia activation appears to be the forerunners of focal lesions and to
precede demyelination (Maggi et al., 2014a). Considering the high his-
topathological similarity between marmoset EAE and human MS, this
finding may have an important translational value with respect to MS.
2. Concluding remarks
MRI imaging is believed to be a valid tool to perform an in vivo esti-
mation of brain pathology, avoiding in many cases the requirement of
brain biopsy, a more invasive and morbidity associated technique
(Auriel et al., 2015). MRI in the marmoset EAE gives the unique oppor-
tunity of applying the same imaging protocols generally adopted in the
clinical practice to an experimental model strongly resembling the
human disease, thus shedding light on the histopathological correlates
of theMRfindings and therefore of thedisease.Moreover in themarmo-
set EAE, not only conventional but also non-conventional MRI tech-
niques can be obtained at ultra-high field strength with important
implications for the development of new imaging markers of disease.
In addition availability in the marmoset EAE of premorbid images, of
longitudinal MRI protocols as well as of prompt imaging-
histopathology correlations, allow to elucidate the pathological process-
es underlying the development of lesions in the CNS. Finally, given the
strong environmental, immunological and histopathological similarities
between the two diseases, results obtained in the marmoset can be re-
liably translated to the human disease helping to elucidate the complex
pathogenesis of MS and improving the identification and development
of new therapeutics.
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